ParkinsonCanadaV1, Main, Exploration, bibRecord, 003270

A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome

Identifieur interne : 003270 ( Main/Exploration ); précédent : 003269; suivant : 003271

A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome

Auteurs : Andrew D. Krahn [Canada] ; George J. Klein [Canada] ; Raymond Yee [Canada]

Source :

Pacing and Clinical Electrophysiology [ 0147-8389 ] ; 2001-08.

RBID : ISTEX:118ADF7F2B55924522341A65CD078ED7E7AA300A

English descriptors

KwdEn :
- Adolescent, Adult, Anti-Arrhythmia Agents (administration & dosage), Anti-Arrhythmia Agents (therapeutic use), Atrial Fibrillation (drug therapy), Atrial Fibrillation (etiology), Double-Blind Method, Electrophysiologic Techniques, Cardiac, Humans, Infusions, Intravenous, Male, Middle Aged, Phenethylamines (administration & dosage), Phenethylamines (therapeutic use), Pilot Projects, Sulfonamides (administration & dosage), Sulfonamides (therapeutic use), Tachycardia, Atrioventricular Nodal Reentry (drug therapy), Tachycardia, Atrioventricular Nodal Reentry (etiology), Wolff-Parkinson-White Syndrome (complications), Wolff-Parkinson-White Syndrome (drug therapy), atrial fibrillation, dofetilide, supraventricular tachycardia, wolff‐parkinson‐white syndrome.
MESH :
- chemical , administration & dosage : Anti-Arrhythmia Agents, Phenethylamines, Sulfonamides.
- chemical , therapeutic use : Anti-Arrhythmia Agents, Phenethylamines, Sulfonamides.
- complications : Wolff-Parkinson-White Syndrome.
- drug therapy : Atrial Fibrillation, Tachycardia, Atrioventricular Nodal Reentry, Wolff-Parkinson-White Syndrome.
- etiology : Atrial Fibrillation, Tachycardia, Atrioventricular Nodal Reentry.
- Adolescent, Adult, Double-Blind Method, Electrophysiologic Techniques, Cardiac, Humans, Infusions, Intravenous, Male, Middle Aged, Pilot Projects.

Abstract

KRAHN, A.D., et al.: A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome. Pharmacological conversion of arrhythmias in Wolff‐Parkinson‐White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18–63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo‐controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.

Url:

https://api-v5.istex.fr/document/118ADF7F2B55924522341A65CD078ED7E7AA300A/fulltext/pdf

DOI: 10.1046/j.1460-9592.2001.01258.x

Affiliations:

Canada

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title>
<author><name sortKey="Krahn, Andrew D" sort="Krahn, Andrew D" uniqKey="Krahn A" first="Andrew D." last="Krahn">Andrew D. Krahn</name>
</author>
<author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name>
</author>
<author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:118ADF7F2B55924522341A65CD078ED7E7AA300A</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1046/j.1460-9592.2001.01258.x</idno>
<idno type="url">https://api-v5.istex.fr/document/118ADF7F2B55924522341A65CD078ED7E7AA300A/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000137</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000137</idno>
<idno type="wicri:Area/Istex/Curation">000137</idno>
<idno type="wicri:Area/Istex/Checkpoint">001099</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001099</idno>
<idno type="wicri:doubleKey">0147-8389:2001:Krahn A:a:randomized:double</idno>
<idno type="wicri:Area/Main/Merge">003752</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11523612</idno>
<idno type="wicri:Area/PubMed/Corpus">001560</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001560</idno>
<idno type="wicri:Area/PubMed/Curation">001560</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001560</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001560</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001560</idno>
<idno type="wicri:Area/Ncbi/Merge">000177</idno>
<idno type="wicri:Area/Ncbi/Curation">000177</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000177</idno>
<idno type="wicri:doubleKey">0147-8389:2001:Krahn A:a:randomized:double</idno>
<idno type="wicri:Area/Main/Merge">003602</idno>
<idno type="wicri:Area/Main/Curation">003270</idno>
<idno type="wicri:Area/Main/Exploration">003270</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome</title>
<author><name sortKey="Krahn, Andrew D" sort="Krahn, Andrew D" uniqKey="Krahn A" first="Andrew D." last="Krahn">Andrew D. Krahn</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Cardiology, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Pacing and Clinical Electrophysiology</title>
<idno type="ISSN">0147-8389</idno>
<idno type="eISSN">1540-8159</idno>
<imprint><publisher>Blackwell Futura Publishing, Inc.</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2001-08">2001-08</date>
<biblScope unit="volume">24</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="1258">1258</biblScope>
<biblScope unit="page" to="1260">1260</biblScope>
</imprint>
<idno type="ISSN">0147-8389</idno>
</series>
<idno type="istex">118ADF7F2B55924522341A65CD078ED7E7AA300A</idno>
<idno type="DOI">10.1046/j.1460-9592.2001.01258.x</idno>
<idno type="ArticleID">PACE1258</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0147-8389</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Anti-Arrhythmia Agents (administration & dosage)</term>
<term>Anti-Arrhythmia Agents (therapeutic use)</term>
<term>Atrial Fibrillation (drug therapy)</term>
<term>Atrial Fibrillation (etiology)</term>
<term>Double-Blind Method</term>
<term>Electrophysiologic Techniques, Cardiac</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Phenethylamines (administration & dosage)</term>
<term>Phenethylamines (therapeutic use)</term>
<term>Pilot Projects</term>
<term>Sulfonamides (administration & dosage)</term>
<term>Sulfonamides (therapeutic use)</term>
<term>Tachycardia, Atrioventricular Nodal Reentry (drug therapy)</term>
<term>Tachycardia, Atrioventricular Nodal Reentry (etiology)</term>
<term>Wolff-Parkinson-White Syndrome (complications)</term>
<term>Wolff-Parkinson-White Syndrome (drug therapy)</term>
<term>atrial fibrillation</term>
<term>dofetilide</term>
<term>supraventricular tachycardia</term>
<term>wolff‐parkinson‐white syndrome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Arrhythmia Agents</term>
<term>Phenethylamines</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Arrhythmia Agents</term>
<term>Phenethylamines</term>
<term>Sulfonamides</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Wolff-Parkinson-White Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Atrial Fibrillation</term>
<term>Tachycardia, Atrioventricular Nodal Reentry</term>
<term>Wolff-Parkinson-White Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Atrial Fibrillation</term>
<term>Tachycardia, Atrioventricular Nodal Reentry</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Double-Blind Method</term>
<term>Electrophysiologic Techniques, Cardiac</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">KRAHN, A.D., et al.: A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome. Pharmacological conversion of arrhythmias in Wolff‐Parkinson‐White (WPW) syndrome is often frequently undertaken. Current antiarrhythmic drugs used for conversion can be associated with significant side effects and variable efficacy. Fifteen male patients (mean age 34, range 18–63 years) with WPW syndrome and atrial fibrillation or AVRT induced in the electrophysiology laboratory were enrolled in a prospective, randomized, placebo‐controlled crossover study. Patients were randomized to one of two doses of intravenous dofetilide or placebo. Patients who failed to respond to this initial infusion received a second higher dose infusion of dofetilide. With the initial infusion, six of ten dofetilide patients converted to sinus rhythm compared to one of five placebo patients. After a second infusion of dofetilide for placebo patients and higher dose dofetilide for low dose dofetilide patients, the overall conversion rate was 71% with dofetilide compared with 20% for placebo (P = 0.046). Atrial fibrillation converted to sinus rhythm in 82% of patients who received dofetilide. Intravenous dofetilide was safe and effective at converting induced atrial fibrillation in patients with WPW syndrome.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Krahn, Andrew D" sort="Krahn, Andrew D" uniqKey="Krahn A" first="Andrew D." last="Krahn">Andrew D. Krahn</name>
</noRegion>
<name sortKey="Klein, George J" sort="Klein, George J" uniqKey="Klein G" first="George J." last="Klein">George J. Klein</name>
<name sortKey="Yee, Raymond" sort="Yee, Raymond" uniqKey="Yee R" first="Raymond" last="Yee">Raymond Yee</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003270 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003270 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:118ADF7F2B55924522341A65CD078ED7E7AA300A
   |texte=   A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome

A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Efficacy and Safety of Intravenously Administered Dofetilide in Patients with Wolff‐Parkinson‐White Syndrome

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.